Clinical Trials · NCT07457164
A Study Investigating the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Teverelix DP, a Gonadotropin-releasing Hormone (GnRH) Antagonist, in Patients With Advanced Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Not Yet Recruiting
- Sponsor
- Antev Ltd.
- Enrollment
- 40
- Start date
- Jul 2026
- Locations
- See registry
- Primary endpoint
- To evaluate the efficacy of a dosing regimen of teverelix DP in attaining by Day 29 and sustaining to Day 155 castration rate